BioSpace News Archive

RaySearch’s founder and CEO, Johan Löf, has sold 100,000 Class B shares in RaySearch Laboratories AB during the period of December 27-31, 2021.

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its participation in the following conferences in January 2022.

Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine.

The company provides a 10-minute brain screening and AI-generated report through their press conference and VIP Tour Program.

Baudax Bio, Inc. announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 109,250 shares of Baudax Bio’s common stock and restricted stock units covering 31,900 shares of Baudax Bio’s common stock to 14 newly-hired employees, with a grant date of December 29, 2021.

R1 RCM Inc. today announced its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 11:15 am ET.

Nutriband Inc., has announced that the Korean Intellectual Property Office has fully issued its patent titled “Abuse and Misuse Deterrent Transdermal System” which is related to the Company’s lead technology AVERSA™.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research published to the preprint server bioRxiv, describing the structural basis and magnitude by which the new SARS-CoV-2 Omicron variant.

BIOLIFE4D Corporation today announced that it intends to submit a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission in early 2022 for a proposed underwritten public offering of its common stock.

Applied UV, Inc. today announced the closing of its previously announced underwritten public offering of 2,666,667 shares of common stock.